![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » BENITEC AND PROMEGA SETTLE LITIGATION
BENITEC AND PROMEGA SETTLE LITIGATION
August 23, 2005
Benitec Ltd. (ASX: BLT) and Promega Corporation announced today the settlement of their contract dispute pending in the US District Court of Delaware, Benitec Australia Ltd. v. Promega Corporation, et al. (Case No. 04-174-JJF). As part of the settlement, Promega will hold a worldwide non-exclusive license to make and sell DNA-directed RNAi (ddRNAi) based research products. Promega will also receive payment in the form of cash and continued royalties from certain sublicenses.
PR Newswire (http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/08-22-2005/0004091899&EDATE=)
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
21Oct